These novel irreversible inhibitors of TG2, such as NC9 and VA4 [114], which specifically react with Cys-277 in the TG2 transamidation site and inhibit both transamidation and GTP-binding activities, are potent anticancer agents that inhibit the survival of cancer stem cells [115]. This evidence concerns the gene TGM2 and cancer.